Hemophiliac Mouse Plasma Levels of Antihuman FVIII Antibodies
Genotype . | Mouse No. . | Time of Sample Collection (wk) . | Factor VIII Levels (mU/mL) . | Antihuman FVIII Antibody Levels (ng/mL) . |
---|---|---|---|---|
Ex 16 KO | Prebleed | (−) | <50 | |
1 | 12 | 277 | 52 | |
16 | (−) | 54 | ||
Prebleed | (−) | <50 | ||
2 | 12 | 245 | 51 | |
16 | 26 | 60 | ||
Prebleed | (−) | <50 | ||
3 | 16 | 208 | <50 | |
20 | 33 | 62 | ||
Prebleed | (−) | <50 | ||
4 | 8 | 1983 | 53 | |
24 | 300 | 79 | ||
Prebleed | (−) | <50 | ||
5 | 12 | 184 | 62 | |
16 | (−) | 93 | ||
Ex 17 KO | Prebleed | (−) | <50 | |
6 | 2 | 136 | 53 | |
6 | 33 | 51 | ||
Prebleed | (−) | <50 | ||
7 | 12 | 240 | 97 | |
16 | (−) | 76 | ||
Prebleed | (−) | <50 | ||
8 | 12 | 554 | 58 | |
24 | 318 | 84 | ||
Prebleed | (−) | 62 | ||
9 | 20 | 242 | <50 | |
24 | 24 | 87 |
Genotype . | Mouse No. . | Time of Sample Collection (wk) . | Factor VIII Levels (mU/mL) . | Antihuman FVIII Antibody Levels (ng/mL) . |
---|---|---|---|---|
Ex 16 KO | Prebleed | (−) | <50 | |
1 | 12 | 277 | 52 | |
16 | (−) | 54 | ||
Prebleed | (−) | <50 | ||
2 | 12 | 245 | 51 | |
16 | 26 | 60 | ||
Prebleed | (−) | <50 | ||
3 | 16 | 208 | <50 | |
20 | 33 | 62 | ||
Prebleed | (−) | <50 | ||
4 | 8 | 1983 | 53 | |
24 | 300 | 79 | ||
Prebleed | (−) | <50 | ||
5 | 12 | 184 | 62 | |
16 | (−) | 93 | ||
Ex 17 KO | Prebleed | (−) | <50 | |
6 | 2 | 136 | 53 | |
6 | 33 | 51 | ||
Prebleed | (−) | <50 | ||
7 | 12 | 240 | 97 | |
16 | (−) | 76 | ||
Prebleed | (−) | <50 | ||
8 | 12 | 554 | 58 | |
24 | 318 | 84 | ||
Prebleed | (−) | 62 | ||
9 | 20 | 242 | <50 | |
24 | 24 | 87 |
Plasma was collected at the indicated times from the exon 16–(Ex 16 KO) and exon 17–disrupted (Ex 17 KO) mice treated with Av3H8101 (6 × 1010 particles/mouse) represented in Fig 3. Plasma was analyzed for FVIII biological activity and for the presence of antihuman FVIII antibodies by ELISA. For the antibody analysis, plasma samples were diluted 1:10, and the limit of sensitivity of the assay was 50 ng/mL. (−) represents a FVIII activity level of less than 1% of that detected in a normal mouse plasma sample analyzed in parallel in each assay.